Ourotech's competitors

Ourotech's competitors include Heat Biologics, Aeglea Biotherapeutics, Immune Design and ImmunoGen
Add company...
Ourotech
Ourotech is changing the way cancer drugs are tested for the most innovative treatments.
Heat Biologics
Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic “off-the-shelf” cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.
Aeglea Biotherapeutics
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.
Immune Design
Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases.
ImmunoGen
ImmunoGen engages in the research and development of antibody-based anticancer therapeutics using its targeted antibody payload technology.
Founding Date
Founding Date
2015
Founding Date
2008
Founding Date
2013
Founding Date
2008
Founding Date
1981
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Waterloo, CA HQ
Locations
Durham, US HQ
Locations
Austin, US HQ
Locations
Seattle, US HQ
South San Francisco, US
Locations
Waltham, US HQ
Norwood, US
Brentwood, US
Employees
Employees
4
Employees
19 21% decrease
Employees
38 27% increase
Employees
50
Employees
308
Valuation ($)
Valuation ($)
N/A
Valuation ($)
11.6 m
Valuation ($)
99.8 m
Valuation ($)
85.8 m
Valuation ($)
982.3 m
Facebook followers
Facebook followers
503
Facebook followers
111
Facebook followers
N/A
Facebook followers
N/A
Facebook followers
N/A
Twitter followers
Twitter followers
273
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
387

Financial

Net income
Net income
N/A
Net income
($13m) (FY, 2016)
Net income
($21.7m) (FY, 2016)
Net income
N/A
Net income
($144.8m) (FY, 2016)

Operating

Phase I Trials
Phase I Trials
N/A
Phase I Trials
N/A
Phase I Trials
2 (FY, 2016)
Phase I Trials
1 (FY, 2016)
Phase I Trials
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles